Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LHW090 in resistant hypertension
2015-001890-42Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in resistant hypertension (RH) and essential hypertension comparing LHW090 with Placebo (2 arms). Primary endpoint: Safety endpoints. Started Oct 2015; status: completed.
02
Drugs
LHW090
03
Conditions
resistant hypertension (RH)essential hypertension
Beyond the preview
Go deeper on 2015-001890-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001890-42.